# TORL BioTherapeutics

Source: https://onco.cc/companies/torl-biotherapeutics/  
OnCo record `torl-biotherapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

TORL BioTherapeutics is a US-based biotechnology company that leads 3 cancer trials in OnCo, testing the antibody-drug conjugates TORL-1-23 (ixotatug vedotin) and TORL-5-700 in non-Hodgkin lymphoma and ovarian cancer.

## Summary

TORL BioTherapeutics develops antibody-drug conjugates for cancer, drawing on a research partnership with the Slamon laboratory at UCLA. Its lead programme TORL-1-23 (ixotatug vedotin) targets claudin 6 in solid tumours and is in phase 2 for platinum-resistant ovarian cancer; TORL-5-700 is an earlier-stage ADC. On ClinicalTrials.gov it is the lead sponsor of 3 trials recorded in OnCo: NCT07439653 (phase 1/2, A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma), NCT06690775 (phase 2, CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.) and NCT07322094 (phase 1/2, CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemothera...). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-17
- Also known as: TORL Biotherapeutics, LLC
- Tags: ctgov-sponsor
- HQ: Culver City, California
- Type: biotech
- Website: https://torlbio.com/

## Sources

- Official website: https://torlbio.com/
- ClinicalTrials.gov: trials led by TORL BioTherapeutics: https://clinicaltrials.gov/search?lead=TORL%20Biotherapeutics%2C%20LLC

## Connected records

- cancers: [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/), [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Pegfilgrastim](https://onco.cc/drugs/pegfilgrastim/)
- trials: [A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma](https://onco.cc/trials/nct07439653/), [CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.](https://onco.cc/trials/nct06690775/), [CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ov](https://onco.cc/trials/nct07322094/)

---
JSON: https://onco.cc/api/v1/entities/torl-biotherapeutics.json